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Introduction: Thrombotic microangiopathic disorders (TMA's) consist of ﬁve overlapping disorders: severe pre-
eclampsia; HELLP (haemolysis, elevated liver enzyme, and low platelet count) syndrome; thrombotic thrombo-
cytopenic purpura (TTP); haemolytic–uremic syndrome (HUS) and systemic lupus erythematosus (SLE). Al-
though several case reports are published on TTP during pregnancy, none of them has described TTP in the
postpartum period.
Case presentation:Wepresent a case report that illustrates the clinical difﬁculties and uncertainties in diagnosing
TTP in a peripartum period. After repeatedly borderline ADAMTS13 tests and deteriorating TMA abnormalities in
the ﬁrst 72 h postpartum, treatment with plasma ﬁltration, fresh frozen plasma and prednisolone resulted in a
quick clinical and laboratory response.
Conclusion: Treatment for TTP should be strongly considered in case of an on-going TMA more than 72 h after
delivery.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Thrombocytopenia is a common ﬁnding during pregnancy. Isolated
thrombocytopenia has a vast aetiology, but in most cases it is mild and
pregnancy induced. Sometimes thrombocytopenia is accompanied by
schistocytes in the blood smear. This is of clinical importance because
their presence indicates an endothelial dysfunction, which is referred
to as thrombotic microangiopathy (TMA) [1]. The differential diagnosis
of isolated thrombocytopenia is quite different from the differential di-
agnosis of TMA's: 1) severe pre-eclampsia; 2) HELLP syndrome
(Coombs-negative haemolysis, elevated liver enzymes and low platelet
count) [1]; 3) thrombotic thrombocytopenic purpura (TTP); 4)
haemolytic–uremic syndrome (HUS) [1–3] and 5) systemic lupus ery-
thematosus (SLE) [4]. To the concerned physicians these ﬁve entities to-
gether are a diagnostic challenge in pregnancy because of their
overlapping features and the requirement of different treatment
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. This is an open access article underHere we describe a case of postpartum thrombocytopenia caused by
TMA in pregnancy, in which the difﬁculties in establishing the cause of
the TMA are highlighted.
2. Case Presentation
A 27 year old Caucasian woman, gravida 1, was admitted to
the hospital for induction of labour because she was nearly post-term
(40 + 5 weeks). Cardiotocography (CTG) on admission was non-
reassuring with a saltatory pattern. Her blood pressure was 110/
70 mm Hg on the day of admission and her medical history comprised
erysipelas with lymphangitis, and recurrent sinusitis due to a septum de-
viation. Her membranes were ruptured artiﬁcially and the amniotic ﬂuid
was meconium-stained. CTG was optimal during labour, showing no
signs of foetal distress. She received 150 mg of pethidine (meperidine)
s.c. for pain. The second stage took 45 min and a healthy son was born.
He had a birthweight of 3760 g and theApgar-scoreswere 7 immediately
after birth, and 10 after ﬁve insufﬂations with oxygen. After delivery 10 U
of oxytocin s.c. was administered and the placenta was delivered 30 min
later. A total blood loss of 300 mL was documented.
Twenty-three minutes later her blood pressure declined to 58/
32 mm Hg, the heart rate was 115 bpm and O2-saturation was 98%.
She also felt drowsy and at physical examination the uterus was well
contracted. She received oxygen, 20 U of oxytocin s.c., 0.4 mg of
naloxone i.v., intravenous infusion with iso-osmotic saline, and plasma
replacement ﬂuid (Voluven), which raised the blood pressure to 111/the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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(normal 7.5–10 mmol/l), and her platelet count was 33 × 109/L (150–
400 × 109/L), while platelet count was 154 × 109/L forty-ﬁve days be-
fore delivery. During the day a total blood loss of 1500mLwas observed,
her blood pressure stayed 108/69 mm Hg and her uterus was well
contracted, so no action was undertaken. In the next days haemoglobin
dropped to 3.5 mmol/L and platelet count to 11 × 109/L. Additional lab-
oratory parameters demonstrated haptoglobulin b 0.3 g/L (0.3–2.0 g/L),
creatinine 58 μmol/L (45–84 μmol/L), ﬁbrinogen 3.9 g/L (2.0–4.0 g/L),
D-dimer 5.92 mg/L (b0.5 mg/L), APTT 33 s (b32 s), PT 10 s (8–11 s),
uric acid 0.39 mmol/L (0.12–0.34 mmol/L), ASAT 64 U/L (b31 U/L),
ALAT 39 U/L (b31 U/L), LDH 1487 U/L (b450 U/L) and bilirubin
22 μmol/L (b17 μmol/L) (Table 1). The blood cell differentiation
revealed schistocytes and Coombs' test was negative so we concluded
that TMA was caused by HELLP syndrome or TTP. She did not complain
of abdominal pain, but experienced headache, and a strange feeling of
decreased awareness of the things happening around her. She was
transferred to the ICU department and prednisone 100 mg/day was
started. An abdominal ultrasoundwas performedwhich showed no ab-
normalities except for an enlarged right kidney, due to the recent preg-
nancy, and a small amount of free ﬂuid in Morrison's space. The
ADAMTS13 was 11% (cut-off value of b10% for TTP) which made TTP
less obvious and HELLP syndrome remained suspected.
In the ICU department her haemoglobin varied between 3.8 and
4.4 mmol/L, schistocytes were still present, and she received a platelet
transfusion which resulted in an increase of platelets from 9 × 109/L to
31 × 109/L. A repeated ADAMTS13 demonstrated a value of 15% (cut-off
value of b10% for TTP). Because of deteriorating platelets, lack of sponta-
neous improvement after delivery as expected inHELLP syndrome andno
severe liver enzyme abnormalities, HELLP syndrome was rejected, and a
diagnosis of TTP was made. Subsequent plasma ﬁltration and replace-
ment (50 mL/kg) with fresh frozen plasma (FFP) was started on the
sixth day after delivery. The following day our patient felt much more
aware and the platelet count had increased up to 95× 109/L. She received
plasma ﬁltration and FFP once a day for ten consecutive days and predni-
sone was continued. Platelet count normalised and haemolysis declinedTable 1
Explorative laboratory tests drawn on day two.
Variables Value Unit Normal value
Hemoglobin 3.5 mmol/L 7.5–10.0
Reticulocytes 3.0 % 0.0–2.5
Haptoglobin b0.3 g/L 0.3–2.0
Ferritin 329 μg/L 20–150
Vitamin B12 193 pmol/L 130–700
Folate 35 nmol/L ≥5
Platelets 11 ×109/L 150–400
APTT 33 s b32
Prothrombin time (PT) 10 s 8–11
Fibrin 3.9 g/L 2.0–4.0
D-dimers 5.92 mg/L b0.5
Leucocytes 9.4 ×109/L 4.3–10.0
Basophils 0 % 0–1
Eosinophils 0 % 0–5
Rods 3 % 0–5
Segments 72 % 40–70
Lymphocytes 16 % 20–45
Monocytes 5 % 2–8
Schistocytes ++
ADAMTS13 11 % b10
Creatinine 58 μmol/L 45–84
Urea 5.4 mmol/L 2.5–6.4
Albumin 21 g/L 35–50
Bilirubin 23 μmol/L b17
γ-GT 9 U/L b35
AF 112 U/L b120
ASAT 64 U/L b31
ALAT 38 U/L b31
LDH 1318 U/L b450
CRP 55 mg/L 0–10(Fig. 1), so that she could be discharged from the hospital after two
weeks in a good clinical condition without any complaints, and without
signs of Coombs-negative haemolysis or schistocytes.
As an outpatient the plasma ﬁltration and plasma replacement was
given three times a week in the ﬁrst week and two times a week in
the second week after which it was stopped. The prednisone dose was
tapered and ﬁnally stopped two months after start without signs of re-
lapse of TTP. After 9 months a repeated ADAMTS13 was 25%, which
raised a suspicion of the Upshaw–Schulman syndrome.
3. Discussion
This case report describes a 27 year old woman with a life-
threatening ongoing thrombocytopenia after delivery caused by TTP.
The ADAMTS13 level of 25% nine months after delivery is suspicious
for the Upshaw–Schulman syndrome. This is congenital TTP caused by
a mutation in the ADAMTS gene on chromosome 9q34 [5]. In these pa-
tients, pregnancy seems to induce thrombocytopenia in the second or
third trimester, often followed by TTP [6].
This case describes a life-threatening thrombocytopenia of pregnan-
cy and peripartum, which is often important to distinguish frommilder
and physiologic forms of thrombocytopenia. Important in thrombocyto-
penia of pregnancy is to establish the presence of TMA and in the case of
TMA to establish the underlying disorder (Table 2). In this case, the
thrombocytopenia was noticed directly after delivery, but a complete
evaluation was started on the second day which contributed to a
delay in the diagnosis of TTP. Thus we recommend more aggressive
evaluation of new onset peripartum thrombocytopenia. The postpar-
tum presentation of severe thrombocytopenia and Coombs-negative
haemolytic anaemiawas ﬁrst attributed to an atypical HELLP syndrome.
Because of the presence of schistocytes in the blood smear and an
ADAMTS13 level of 11%, with a cut-off value of b10%, TTPwas discarded
at ﬁrst. A repeated ADAMTS13 revealed a value of 15%, bywhich no def-
inite diagnosis of TTP could be made. Because of deteriorating platelets
and lack of laboratory abnormalities improvementmore than 72 h after
delivery HELLP syndrome was considered unlikely and treatment for
TTPwas initiated. Because of rapid clinical and laboratory improvement
in the hours following plasma ﬁltration, a diagnosis of TTP was made.
TTP and HUS are rare entities and it is estimated that it occurs in
b1:100.000 pregnancies [7]. In a retrospective study between 1955
and 2006 byMartin and colleagues, 166 reports of pregnancy associated
TTP were found in the literature [3]. Although TTP mostly presented in
the second and early third trimester of the pregnancy (55.5%), in 21 of
166 cases (12.7%) the onset of TTP occurred postpartum. It is estimated
that in the era before plasma infusions and plasma exchange maternal
mortality was as high as 60% [3]. Nowadays the maternal mortality is
0–15%, which is mainly due to complications of plasma exchange ther-
apy [8]. Furthermore, there is a difference ofmaternal outcomebetween
patients already knownwith TTP, and patients who develop TTP for the
ﬁrst time during pregnancy, or in the postpartum period, because of
delay in conﬁrming the diagnosis and thus treatment [7]. Pregnancy in-
duced TTP is not only associated with maternal death and morbidity,
but also with perinatal loss (17%), perinatal mortality (454:1.000), and
preterm delivery [3,7].
The classical features of TTP consist of the pentad: thrombocytope-
nia, microangiopathic haemolytic anaemia with schistocytes in the
blood smear, neurologic abnormalities, fever, and renal failure. The
ﬁrst three symptoms frequently occur together (50–75%), but all ﬁve
symptoms rarely occur at the same time, and therefore the pentad is
considered to be out-dated [7–9]. George and colleagues showed that
among eighteen patients diagnosed with TTP, and an ADAMTS13 level
of b5% (which is speciﬁc for TTP), abdominal pain, nausea, vomiting,
and/or diarrhoea were the most presenting complaints [9]. For physi-
cians it is hard to diagnose TTP based on these unspeciﬁc symptoms
and therefore laboratory results provide the diagnosis. The ‘new’ diag-
nostic triad of 1) thrombocytopenia, 2) microangiopathic haemolytic
Fig. 1. Graph of the course of the haemoglobin, platelet count, LDH and reticulocytes.
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9]. This allows physicians to diagnose TTP rapidly, which can be of life-
saving importance. A negative Coombs' test may support the diagnosis
together with a low haptoglobin level [10,11]. Neurologic symptoms
are difﬁcult to diagnose and are usually vague [7].
TTP is caused by a deﬁciency of the thirteenth member of a
disintegrin-like and metalloprotease with thrombospondin type 1 mo-
tifs 13 (ADAMTS13), which normally cleaves the plasma glycoprotein
Von Willebrand factor (VWF) [1–3,7,12]. In TTP VWF is not cleaved
which results in ultra-large VWF-multimers that cause platelet aggrega-
tion, thrombocytopenia and Coombs-negative haemolysis (TMA). A
plasma ADAMTS13 activity level of b5% or b10%, depending on the
assay, is speciﬁc for TTP [2,9]. However, George and colleagues conclud-
ed that only a cut-off value of b5% is highly speciﬁc for TTP [9]. A cut-off
value of b10% included less false negatives (especially relapses of TTP),
but logically alsomore false positives (e.g. severe sepsis or disseminated
malignancy). Deﬁciency of ADAMTS13 in TTP can be a result of genetic
mutations (e.g. Upshaw–Schulman syndrome), autoimmune disorder
or acquired inhibitors [2,9,10,13]. The measurement of ADAMTS13 ac-
tivity can be helpful in case of TTP occurrence in pregnancy, although
decreased ADAMTS13 levels are associated with normal pregnancy
and with HELLP syndrome [12,14]. Hulstein and colleagues found a sig-
niﬁcant decreased ADAMTS13 in patients diagnosed with HELLP syn-
drome (n = 14) when compared with patients with a normal
pregnancy (n=9) [14]. Other studies show that ADAMTS13 activity be-
tween 10 and 50% is compatible with a near term of normal pregnancy
and that fromweek twelve of gestation there is a signiﬁcant decrease in
activity compared to non-pregnant women [9,12].
Schistocytes are fragmented erythrocytes that are injured by dam-
aged endothelium [11]. It is important to use a threshold of 0.2–0.5%
for schistocytes before suspecting TTP. Furthermore, microscopicTable 2
Differential diagnosis of severe pre-eclampsia/HELLP syn-
drome, reproduced from Sibai (2009) [7]with permission,
and with slight modiﬁcations.
- Acute fatty liver of pregnancy
- Thrombotic thrombocytopenic purpura
- Hemolytic–uremic syndrome
- Exacerbation of lupus erythematosus
- Catastrophic antiphospholipid syndrome
- Systemic viral sepsis (disseminated herpes)
- Systemic inﬂammatory response syndrome (SIRS)
- Disseminated intravascular coagulationdetermination lacks standardization and remains highly observer de-
pendent [15]. However, schistocytes not only are present in TTP, but
may be encountered in other TMA's as well, including SLE [4].
Martin and colleagues performed a prospective study which includ-
ed eighteen women diagnosed with HELLP syndrome [16]. These
women were treated with plasma exchange postpartum because of 1)
persistent evidence of atypical HELLP syndrome N72 h after
delivery (n = 9) or 2) evidence of worsening HELLP syndrome at any
time postpartum in association with single- or multiple-organ injury
(n = 9). Only patients with class 1 HELLP syndrome (platelet
count ≤ 50 × 109/L; ASAT or ALAT ≥ 70 U/L; LDH ≥ 600 U/L) and pro-
gressive anaemia with abnormal red blood cell forms were included.
Two out of nine patients from the second arm (with worsening HELLP
syndrome) died despite the therapy. All patients in the ﬁrst arm
responded well to plasma exchange. An earlier study recommended
that in case of doubt between ongoing HELLP syndrome and TTP after
delivery, one should wait at least 72 h before considering plasmaphere-
sis [17]. McMinn & George support the ‘72-hour policy’ [18]. They pro-
vide additional clinical features for starting with plasma treatment,
especially in pregnant or postpartum women who are more likely to
have TTP-HUS. They recommend to start with plasma therapy if:
- Severe thrombocytopenia and microangiopathic haemolytic anae-
mia progress for more than three days following delivery.
- There are normal coagulation parameters, or resolving disseminated
intravascular coagulation (DIC).
- There are mental status abnormalities (such as confusion, disorien-
tation, stupor, coma).
- There are focal (neurologic) abnormalities (such as aphasia, dysar-
thria, or focal motor deﬁcits).
- There are seizures (in association with progressive postpartum
thrombocytopenia and microangiopathic haemolytic anaemia).
- There is oliguric acute renal failure (in association with progressive
postpartum thrombocytopenia and microangiopathic haemolytic
anaemia).
TTP that occurs during pregnancy carries the risk of relapse after de-
livery as well as in subsequent pregnancies. Patients should be
instructed about recognizing symptoms and reporting them immedi-
ately to a physician [7]. Relapses are common among those with con-
genital ADAMTS13 deﬁciency (approximately 40% will relapse), but
very rare among patients without congenital ADAMTS13 deﬁciency.
Most of the relapses of non-congenital TTP occur within the ﬁrst year
and are a single event. Relapses after four years are rarely seen [9].
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New onset thrombocytopenia during pregnancy should have a thor-
ough work-up, including a peripheral blood smear to look for
schistocytes, to exclude thrombotic microangiopathy's (TMA's). Also
treatment for TTP should be strongly considered in case of an on-
going TMA more than 72 h after delivery.
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